Furthermore, observation of the NF-kB inhibitor NFKBIA—autoregulated by NF-kB and therefore reflecting activation levels of the signaling pathway—demonstrates overexpression in the majority of MDS patients’ MSCs. Here, NFKB1 is linked to myelodysplastic syndrome.